期刊文献+

免疫稳态理念应贯穿于重症肌无力的治疗 被引量:6

原文传递
导出
摘要 重症肌无力( myasthenia gravis, MG)是典型的抗体介导的、细胞免疫依赖的、补体参与的器官特异性自身免疫性疾病。临床特征多为眼外肌受累首发,逐渐波及球部和四肢肌肉,甚至出现呼吸肌无力,危及生命,有活动后加重,休息后减轻和晨轻暮重等特点。20世纪90年代以前,乐观地认为MG的致病性自身抗体明确,最有可能成为研究自身免疫性疾病发病机制的突破口。然而,临床上针对MG患者体内自身抗体的治疗策略并未取得预期的治疗效果。因此认为MG的发病机制可能涉及更为复杂的免疫系统功能紊乱。由于病情的波动性和严重性,尚没有统一的治疗指南,有必要提出治疗上凸显的问题进行讨论。一。
作者 刘卫彬
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第17期1281-1282,共2页 National Medical Journal of China
  • 相关文献

参考文献7

  • 1许贤豪,王化冰.重症肌无力及其他神经肌肉传递障碍疾病.//王维治.神经病学.北京:人民卫生出版社,2006:1173-1198.
  • 2Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol, 2009,8:475-490.
  • 3冯慧宇,刘卫彬,邱力,何雪桃,张莹,黄鑫,黄如训.血浆置换治疗重症肌无力危象的相关因素分析[J].中华医学杂志,2010,90(47):3343-3346. 被引量:6
  • 4Huang X, Liu WB, Men LN, et al. Clinical features of myasthenia gravis in southern China: a retrospective review of 2154 cases over 22 years. Neurol Sci,2012. [Epub ahead of print ].
  • 5Somnier FE. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology, 2005,65 : 928 - 930.
  • 6Dorababu P, Nagesh N, Linga VG, et al. Epistatic interactions between thiopurine methyhransferase ( TPMT ) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6- mercaptopufine toxicity in Indian children with acute lymphoblastic leukemia. Eur J Clin Pharmacol, 2012,68: 379- 387.
  • 7Chen X J, Qiao J, Xiao BG, et al. The significance of titin antibodies in myasthenia gravis correlation with thymoma and severity of myasthenia gravis. J Neurol, 2004, 251 : 1006-1011.

二级参考文献11

  • 1刘卫彬,门丽娜,夏强,何雪桃,黄如训.重症肌无力患者免疫指标检测及其临床评价[J].中华医学杂志,2006,86(47):3331-3334. 被引量:9
  • 2Sarkar BK,Sengupta P,Sarkar UN.Surgical outcome in thymic tumors with myasthenia gravis after plasmapheresis-a comparative study.Interact Cardiovasc Thorac Surg,2008,7:1007-1010.
  • 3El-Bawab H,Hajjar W,Pday M,et al.Plasmapheresis before thymectomy in myasthenia gravis:routine versus selective protocols.Eur J Cardiothorac Surg,2009,35:392-397.
  • 4Yeh JH,Chiu HC.Plasmapheresis in myasthenia gravis.A comparative study of daily versus alternately daily schedule.Acta Neurol Scand,1999,99:147-151.
  • 5Yeh JH,Chiu HC.Optimal volume of processed plasma and total number of selective plasmapheresis sessions in the treatment of patients with severe generalized myasthenia gravis.J Clin Apher,1999,14:177-180.
  • 6Yeh JH,Chiu HC.Double filtration plasmapheresis in myasthenia gravis-analysis of clinical efficacy and prognostic parameters.Acta Neurol Scand,1999,100:305-309.
  • 7Chiu HC,Yeh JH,Chen WH.Pulmonary function study of myasthenia-gravis patients treated with double-filtration plasmapheresis.J Clin Apher,2003,18:125-128.
  • 8Yeh JH,Chen WH,Chiu HC,et al.MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis.J Neurol Sci,2007,263:191-193.
  • 9Evoli A,Tonali PA,Padua L,et al.Clinical correlates with antiMuSK antibodies in generalized seronegative myasthenia gravis.Brain,2003,126:2304-2311.
  • 10Trikha I,Singh S,Goyal V,et al.Comparative efficacy of low dose,daily versus alternate day plasma exchangein severe myasthenia gravis.A randomised trial.J Neurol,2007,254:989-995.

共引文献8

同被引文献44

  • 1刘睿,李柱一,王桂平,许汉鹏,施新猷,鞠躬.大鼠EAMG模型眼外肌下调差异基因的初步筛选[J].中国临床神经科学,2004,12(3):223-225. 被引量:5
  • 2刘卫彬,门丽娜,夏强,何雪桃,黄如训.重症肌无力患者免疫指标检测及其临床评价[J].中华医学杂志,2006,86(47):3331-3334. 被引量:9
  • 3刘卫彬,王化冰,许贤豪.重症肌无力//王维治.神经病学.北京:人民卫生出版社.2013:1509-1544.
  • 4Smolen JS,Aletaha D,Bijlsma JW,Breedveld FC,Boumpas D,Burmester G,Combe B,Cutolo M,de Wit M,Dougados M,Emery P,Gibofsky A,Gomez-Reino J J,Haraoui B,Kalden J,Keystone EC,Kvien TK,McInnes I,Martin-Mola E,Montecucco C,Schoels M,van der Heijde D; T2T Expert Committee.Treating rheumatoid arthritis to target:recommendations of an international task force.Ann Rheum Dis,2010,69:631-637.
  • 5Gregersen PK,Kosoy R,Lee AT,Lamb J,Sussman J,McKee D,Simpfendorfer KR,Pirskanen-Matell R,Piehl F,PanHammarstrom Q,Verschuuren J J,Titulaer M J,Niks EH,Marx A,Str(o)bel P,Tackenberg B,Pütz M,Maniaol A,Elsais A,Tallaksen C,Harbo HF,Lie BA,Raychaudhuri S,de Bakker PI,Melms A,Garchon H J,Willcox N,Hammarstrom L,Seldin MF.Risk for myasthenia gravis maps to a (151) pro→Ala change in TNIP1 and to human leukocyte antigen-B*08.Ann Neurol,2012,72:927-935.
  • 6Li X,Xiao BG,Xi JY,Lu CZ,Lu JH.Decrease of CD4(+)CD25 (high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis.Clin Immunol,2008,126:180-188.
  • 7Marx A,Willcox N,Leite MI,Chuang WY,Schalke B,Nix W,Str(o)bel P.Thymoma and paraueoplastic myasthenia gravis.Autoimmunity,2010,43(5/6):413-427.
  • 8Zhou L,Chong MM,Littman DR.Plasticity of CD4 +T cell lineage differentiation.Immunity,2009,30:646-655.
  • 9Balandina A,Lécart S,Dartevelle P,Saoudi A,Berrih-Aknin S.Functional defect of regulatory CD4(+)CD25 + T cells in the thymus of patients with autoimmune myasthenia gravis.Blood,2005,105:735-741.
  • 10Thiruppathi M,Rowin J,Li Jiang Q,Sheng JR,Prabhakar BS,Meriggioli MN.Functional defect in regulatory T cells in myasthenia gravis.Ann NY Acad Sci,2012,1274:68-76.

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部